Why the study?
Does intravenous cinaciguat improve haemodynamics or dyspnoea in adults hospitalized with acute heart failure syndromes?
Does intravenous cinaciguat improve haemodynamics or dyspnoea in adults hospitalized with acute heart failure syndromes?
Short-term use of intravenous cinaciguat in acute heart failure syndromes caused hypotension without improving dyspnoea or cardiac index, leading to early termination of the trials.
No takes yet. Share an insight, caveat, or question.
Intravenous cinaciguat lacks dyspnoea benefit and risks hypotension in acute HF; challenges further development of soluble guanylate cyclase activators in this setting.
Gheorghiade et al. (2012) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: